Latest News and Press Releases

Arcutis today announced that management will participate in the Morgan Stanley 22nd Annual Global Healthcare Conference.

Arcutis today reported financial results for the quarter ended June 30, 2024, and provided a business update.

Arcutis today reported financial results for the quarter ended June 30, 2024, and provided a business update.

WESTLAKE VILLAGE, Calif., Aug. 02, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in...

Arcutis today announced that it will report second quarter 2024 financial results and provide a business update on Wednesday, August 14, 2024.

Arcutis today announced the signing of a co-promotion agreement with Kowa Pharmaceuticals America, Inc.

Arcutis today announced the commercial launch of ZORYVE® (roflumilast) cream 0.15% for the treatment of mild to moderate atopic dermatitis.

Arcutis today announced the submission of an sNDA in scalp and body psoriasis.

Arcutis will host a KOL virtual event July 29, 2024

Arcutis announced the FDA approval for ZORYVE (roflumilast) cream, 0.15%, for the treatment of atopic dermatitis